⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 24, 2024Future Oncology

The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

Dilek Çağlayan Mehmet Zahid Koçak Çağlayan Geredeli Muhammed Mustafa Atçı Ali Murat Tatlı Sema Sezgin Göksu Melek Karakurt Eryılmaz Murat Araz Mehmet Artaç

View Full Paper

Ask AI

Bookmark

Share

Abstract

Endocrine therapy (ET) plus cyclin-dependent kinase (CDK) 4/6 inhibitors is a standard treatment for hormone receptor (HR) positive HER-2-negative metastatic breast cancer patients. In this study, we aimed to investigate the effect of body mass index (BMI) on progression-free survival (PFS) in patients receiving ET plus CDK 4/6 inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Çağlayan et al. (2024) studied this question.

synapsesocial.com/papers/68e57799b6db643587517c25 https://doi.org/10.1080/14796694.2024.2402212

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The impact of body mass index on the progression free survival of CDK 4/6 inhibitors in metastatic breast cancer patients2024
2The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer2025 · 3 citations
3Abstract PO3-05-09: The impact of body mass index on CDK4/6 inhibitor treatment survival outcomes in metastatic breast cancer2024 · 2 citations
4Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort StudyCohort Study · 2026
5Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials2024 · 10 citations